A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy - npj Precision Oncology
Source : https://www.nature.com/articles/s41698-022-00262-y
Immunotherapies have recently gained traction as highly effective therapies in a subset of late-stage cancers. Unfortunately, only a minority of patients experience the remarkable benefits of immunotherapies, whilst others fail...
Conclusion/Relevance: The miRisk score offers a potential blood-based companion diagnostic for immunotherapy that outperforms tissue-based PD-L1 staining.
Synergistic Effect of Stereotactic Radiotherapy Combined with Karelizumab on Patients with Advanced NSCLC
Source : https://www.hindawi.com/journals/jhe/2022/7875627/
In this paper, synergistic effects of stereotactic radiotherapy (SRS) combined with karelizumab on the patients with advanced NSCLC have been analyzed through extensive experiments. For this purpose, 100 patients with...
Conclusion: SRS combined with karelizumab in the treatment of patients with advanced NSCLC has good curative effect, can evidently inhibit the angiogenesis and tumor growth and metastasis, can evidently improve the quality of life of patients, has a good synergistic effect, and can be widely used in clinic.
Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update
Source : https://article.cjcrcn.org/en/article/doi/10.21147/j.issn.1000-9604.2022.01.03?viewType=HTML
Objective Anti-vascular endothelial growth factor (VEGF) monoclonal antibodies are an effective means of treating non-small cell lung cancer (NSCLC). Here, we aim to update the equivalent efficacy assessment between QL1101...
Conclusions: This study reports the results of a two-year follow-up of a bevacizumab biosimilar, QL1101. The results of this study demonstrated that QL1101 had similar efficacy in treating nonsquamous NSCLC in terms of ORR, PFS, OS and side effects, providing a basis for the clinical application of QL1101.
Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35290596/
Bevacizumab, an anti-VEGF monoclonal antibody, has significantly improved the clinical outcomes of patients with advanced non-squamous NSCLC (ns-NSCLC). However, the safety and efficacy of bevacizumab for elderly patients with advanced...
Conclusion/Relevance: With increased toxicities, the addition of bevacizumab to PP does not improve the overall survival of elderly patients with advanced ns-NSCLC.
Cancer-released exosomal circular RNA circ_0008717 promotes cell tumorigenicity through microRNA-1287-5p/P21-activated kinase 2 (PAK2) axis in non-small cell lung cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35333693/
Circular RNA (circRNA) circ_0008717 has been revealed to promote cell carcinogenesis in non-small cell lung cancer (NSCLC). Exosomal circRNA packaged into exosomes has been defined as a potential diagnostic and...
Conclusion/Relevance: We confirmed that circ_0008717 was incorporated into exosomes in NSCLC cells. Circ_0008717 knockdown inhibited NSCLC tumorigenesis via miR-1287-5p/PAK2 axis, and the extracellular circulating circ_0008717 was transferred through incorporation in exosomes.
Yahoo | Mail, Weather, Search, Politics, News, Finance, Sports & Videos
Source : https://www.yahoo.com
Latest news coverage, email, free stock quotes, live scores and video are just the beginning. Discover more every day at Yahoo!